In a paper published in the journal Neuroscience of Consciousness psychology researchers from the University of Technology Sydney (UTS) worked with 54 participants to examine the effects of surveillance on an essential function of human sensory perception — the ability to detect another person’s gaze.

Lead author, Associate Professor of neuroscience and behaviour Kiley Seymour, said previous research has established the effects on conscious behaviour when people know they are being watched, but the new study provided the first direct evidence that being watched also has an involuntary response.

“We know CCTV changes our behaviour, and that’s the main driver for retailers and others wanting to deploy such technology to prevent unwanted behaviour,” Associate Professor Seymour said.

“However, we show it’s not only overt behaviour that changes — our brain changes the way it processes information.

“We found direct evidence that being conspicuously monitored via CCTV markedly impacts a hardwired and involuntary function of human sensory perception — the ability to consciously detect a face.

“It’s a mechanism that evolved for us to detect other agents and potential threats in our environment, such as predators and other humans, and it seems to be enhanced when we’re being watched on CCTV.

“Our surveilled participants became hyper aware of face stimuli almost a second faster than the control group. This perceptual enhancement also occurred without participants realising it.”

Associate Professor Seymour said that given the increasing level of surveillance in society and the ongoing debates around privacy reform, the study’s findings suggested the need for closer examination of the effects of surveillance on mental processes and on public health more broadly.

“We had a surprising yet unsettling finding that despite participants reporting little concern or preoccupation with being monitored, its effects on basic social processing were marked, highly significant and imperceptible to the participants.

“The ability to rapidly detect faces is of critical importance to human social interactions. Information conveyed in faces, such as gaze direction, enables us to construct models of other people’s minds and to use this information to predict behaviour.

“We see hyper-sensitivity to eye gaze in mental health conditions like psychosis and social anxiety disorder where individuals hold irrational beliefs or preoccupations with the idea of being watched.

“Whilst this investigation was specifically focussed on unconscious social processes, future investigations should explore effects on the limbic system more broadly, which would have more general implications for public mental health and the importance of privacy.”

Now, new research from NYU Tandon faculty including Professor of Electrical and Computer Engineering Davood Shahrjerdi; Herman F. Mark Professor in Chemical and Biomolecular Engineering Elisa Riedo; and Giuseppe de Peppo, Industry Associate Professor in Chemical and Biomolecular Engineering and who was previously at Mirimus, shows it’s possible to develop and build microchips that can not only identify multiple diseases from a single cough or air sample, but can also be produced at scale.

“This study opens new horizons in the field of biosensing. Microchips, the backbone of smartphones, computers, and other smart devices, have transformed the way people communicate, entertain, and work. Similarly, today, our technology will allow microchips to revolutionize healthcare, from medical diagnostics, to environmental health” says Riedo,

“The innovative technology demonstrated in this article uses field-effect transistors (FETs) — miniature electronic sensors that directly detect biological markers and convert them into digital signals — offering an alternative to traditional color-based chemical diagnostic tests like home pregnancy tests,” said Shahrjerdi. “This advanced approach enables faster results, testing for multiple diseases simultaneously, and immediate data transmission to healthcare providers” says Sharjerdi, who is also the Director of the NYU Nanofabrication Cleanroom, a state-of-the-art facility where some of the chips used in this study were fabricated. Riedo and Shahrjerdi are also the co-directors of the NYU NanoBioX initiative.

Field-effect transistors, a staple of modern electronics, are emerging as powerful tools in this quest for diagnostic instruments. These tiny devices can be adapted to function as biosensors, detecting specific pathogens or biomarkers in real time, without the need for chemical labels or lengthy lab procedures. By converting biological interactions into measurable electrical signals, FET-based biosensors offer a rapid and versatile platform for diagnostics.

Recent advancements have pushed the detection capabilities of FET biosensors to incredibly small levels — down to femtomolar concentrations, or one quadrillionth of a mole — by incorporating nanoscale materials such as nanowires, indium oxide, and graphene. Yet, despite their potential, FET-based sensors still face a significant challenge: they struggle to detect multiple pathogens or biomarkers simultaneously on the same chip. Current methods for customizing these sensors, such as drop-casting bioreceptors like antibodies onto the FET’s surface, lack the precision and scalability required for more complex diagnostic tasks.

To address this, these researchers are exploring new ways to modify FET surfaces, allowing each transistor on a chip to be tailored to detect a different biomarker. This would enable parallel detection of multiple pathogens.

Enter thermal scanning probe lithography (tSPL), a breakthrough technology that may hold the key to overcoming these barriers. This technique allows for the precise chemical patterning of a polymer-coated chip, enabling the functionalization of individual FETs with different bioreceptors, such as antibodies or aptamers, at resolutions as fine as 20 nanometers. This is on par with the tiny size of transistors in today’s advanced semiconductor chips. By allowing for highly selective modification of each transistor, this method opens the door to the development of FET-based sensors that can detect a wide variety of pathogens on a single chip, with unparalleled sensitivity.

Riedo, who was instrumental in the development and proliferation of tSPL technology, sees its use here to be further evidence of the groundbreaking way this nanofabrication technique can be used in practical applications. “tSPL, now a commercially available lithographic technology, has been key to functionalize each FET with different bio-receptors in order to achieve multiplexing,” she says.

In tests, FET sensors functionalized using tSPL have shown remarkable performance, detecting as few as 3 attomolar (aM) concentrations of SARS-CoV-2 spike proteins and as little as 10 live virus particles per milliliter, while effectively distinguishing between different types of viruses, including influenza A. The ability to reliably detect such minute quantities of pathogens with high specificity is a critical step toward creating portable diagnostic devices that could one day be used in a variety of settings, from hospitals to homes.

The study, now published by the Royal Society of Chemistry in Nanoscale, was supported by Mirimus, a Brooklyn-based biotechnology company, and LendLease, a multinational construction and real estate company based in Australia. They are working with the NYU Tandon team to develop illness-detecting wearables and home devices, respectively.

“This research shows off the power of the collaboration between industry and academia, and how it can change the face of modern medicine,” says Prem Premsrirut, President and CEO of Mirimus. “NYU Tandon’s researchers are producing work that will play a large role in the future of disease detection.”

“Companies such as Lendlease and other developers involved in urban regeneration are searching for innovative solutions like this to sense biological threats in buildings.” says Alberto Sangiovanni Vincentelli of UC Berkeley, a collaborator on the Project. “Biodefense measures like this will be a new infrastructural layer for the buildings of the future”

As semiconductor manufacturing continues to advance, integrating billions of nanoscale FETs onto microchips, the potential for using these chips in biosensing applications is becoming increasingly feasible. A universal, scalable method for functionalizing FET surfaces at nanoscale precision would enable the creation of sophisticated diagnostic tools, capable of detecting multiple diseases in real time, with the kind of speed and accuracy that could transform modern medicine.

The international research, led by The University of Queensland’s Professor Peter Mumby, measured the success of a natural spawning event in March this year.

“In what came as a surprise, we saw that corals needed to be within 10 metres of one another, and preferably closer than that for fertilisation to take place,” Professor Mumby said.

“We knew corals couldn’t be too far apart, but we found they need to be closer than we’d expected.

“Climate change impacts like bleaching are killing and reducing the density of corals, so we’re concerned that individuals may end up too far apart to reproduce successfully.”

To quantify reproduction success, the team placed containers above 26 coral colonies on a reef in Palau, Micronesia during a time when the mostly hermaphroditic corals released eggs and sperm.

“The containers captured some of each corals’ eggs and drifted to the surface where they followed the tide,” Professor Mumby said.

“Although the eggs could not escape, sperm could enter the container and fertilise the eggs.

“After an hour of drifting, the proportion of fertilised eggs was noted for each type of coral along with the distance to similar established corals.”

Fertilisation averaged 30% when corals were very close, but it declined to less than 10% at a separation of 10 metres and was virtually zero by 20 metres.

Co-author Dr Christopher Doropoulos of the CSIRO, Australia’s national science agency, said coral reproduction was fundamental to population resilience and evolution.

“In the future we may need to help corals continue this key part of their lives,” Dr Doropoulos said.

“Understanding the importance of local neighbourhoods provides tangible targets for interventions like coral restoration.

“Ideally, the density of corals would be monitored at important locations and restoration carried out to return the density back to the levels required for successful reproduction.”

Professor Mumby has been working on efforts to repair damaged coral reefs.

“Our work over the past 5 years on the Great Barrier Reef through the Reef Restoration and Adaptation Program is also helping to define these critical thresholds to help restoration practitioners set targets for density to help maintain coral populations,” he said.

The study was funded by the McCusker Foundation and the Australian Government’s Reef Restoration & Adaptation Program.

The research is published in the Proceedings of the National Academy of Sciences USA (PNAS).

Cisplatin and carboplatin — which have been approved for more than 30 years — are widely used to treat a variety of cancers, including lung, head and neck, breast, bladder, ovarian, uterine, and testicular cancers. When the FDA announced a shortage of cisplatin in February 2023, followed by a shortage of carboplatin in April 2023, it drew attention to the ongoing challenge of generic drug shortages, and prompted major national oncology societies to recommend best practices for priority use and alternative medicines.

“At the time, national surveys showed that most cancer centers in the US were reporting shortages of these platinum chemotherapies, but it wasn’t clear how the shortages were actually affecting patients,” said lead author Jacob B. Reibel, MD, a third-year fellow in Hematology-Oncology. “When we looked at the data on prescribing practices over the shortage period, compared to the previous year, we found that although reporting of the shortages was widespread, it didn’t affect as many patients as we had feared.”

Reibel, senior author Ronac Mamtani, MD, section chief of Genitourinary Cancers, and colleagues, analyzed data from 11,797 adults across the U.S. with advanced solid cancers for which platinum chemotherapy is recommended as the first line of therapy and who began treatment during the one-year period before or during the platinum chemotherapy shortage. Because cisplatin and carboplatin were prioritized for patients with curable cancers during the shortage, the researchers expected that patients with advanced cancers would be most affected by drug availability.

From February 2023 through January 2024, there was a 2.7 percent decrease in platinum chemotherapy use compared to the previous year. This translates into 137 fewer patients in this advanced cancer cohort receiving platinum chemotherapy than expected, and the researchers estimate about 1,000 patients affected overall in the US, based on the rates observed in the study. At the peak of the shortage in June 2023, the decrease was 15.1 percent compared to the previous year. With a median follow-up time of 7.6 months after beginning treatment, there was no difference in mortality compared to the previous year.

Alternative therapies help mitigate the crisis, but are not first choice

The researchers hypothesized that the limited impact on mortality was likely due to the use of effective alternative medications recommended by medical societies, such as immune checkpoint inhibitors, targeted therapy or other forms of chemotherapy. The study did not assess the potential drawbacks of alternative medications, including the financial burden of more expensive non-generic alternatives and side effects of different drugs.

“We always want to prioritize the best treatments that we have for patients, and platinum chemotherapies just happen to also be very cost-effective because they’re generic and have been around for decades,” Mamtani said. “While the alternative options may be effective, we want to be able to provide the ‘standard-of-care’ medications to any patient in need. Even one hundred patients who can’t get the preferred chemotherapy for their cancer type due to supply chain issues is far too many.”

The FDA listed the cisplatin shortage as resolved at the end of June 2024 and carboplatin remains on the shortage list, though the research team found prescribing levels have returned to normal.

The study was funded by the National Institutes of Health (T32CA009679).